Moneycontrol PRO
glenmark pharmaceuticals
Jump to
  • Glenmark launches fixed-dose combination for diabetic patients Apr 25, 2022 11:17 AM IST

    Glenmark launches fixed-dose combination for diabetic patients

    Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement.

  • Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher Apr 14, 2022 04:52 PM IST

    Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 5.1 percent Y-o-Y (down 5.3 percent Q-o-Q) to Rs 3,006.1 crore, according to Prabhudas Lilladher.

  • Glenmark Pharma shares gain on DCGI nod to clinical trial of 'novel' small molecule Apr 11, 2022 10:46 AM IST

    Glenmark Pharma shares gain on DCGI nod to clinical trial of 'novel' small molecule

    Glenmark will initiate Phase 1 clinical trial in India by June 2022 for its small molecule, GRC 54276, a hematopoietic progenitor kinase 1 (HPK1) inhibitor

  • Glenmark Pharmaceuticals gets final USFDA nod for Lacosamide tablet Mar 21, 2022 10:18 AM IST

    Glenmark Pharmaceuticals gets final USFDA nod for Lacosamide tablet

    The approval granted by the US Food & Drug Administration (USFDA) to the company's arm Glenmark Pharmaceuticals Inc, USA, is for Lacosamide tablets of strengths 50 mg, 100 mg, 150 mg and 200 mg, Glenmark said in a statement.

  • Hot Stocks | Here's why Aarti Industries, Glenmark Pharma, ICICI Prudential Gold ETF can give decent returns in short term Feb 22, 2022 07:20 AM IST

    Hot Stocks | Here's why Aarti Industries, Glenmark Pharma, ICICI Prudential Gold ETF can give decent returns in short term

    RRG (Relative Rotation Graphs) analysis indicates expected outperformance from banks, metals and auto sectors and expected underperformance from realty, media and IT. Gold has registered fresh breakout on charts and likely to perform well.

  • Hold Glenmark Pharmaceuticals: target of Rs 550: ICICI Direct Feb 15, 2022 06:36 PM IST

    Hold Glenmark Pharmaceuticals: target of Rs 550: ICICI Direct

    ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 550 in its research report dated February 14, 2022.

  • Glenmark Pharma gets USFDA nod for generic drug Jan 28, 2022 12:12 PM IST

    Glenmark Pharma gets USFDA nod for generic drug

    The drug firm has received final approval by the United States Food & Drug Administration (USFDA) for its product which is a generic version of Bausch Health US LLC’s MetroGel-Vaginal, the drug firm said in a statement.

  • Glenmark Pharma gets USFDA nod for nasal spray to treat seasonal allergic rhinitis Jan 14, 2022 10:15 AM IST

    Glenmark Pharma gets USFDA nod for nasal spray to treat seasonal allergic rhinitis

    The company’s fully-owned unit Glenmark Specialty SA (Switzerland) has received approval from the USFDA for its new drug application (NDA) for Ryaltris, a fixed-dose (metered), prescription, combination nasal spray, Glenmark Pharmaceuticals said in a statement.

  • Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher Jan 13, 2022 03:21 PM IST

    Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 10.3 percent Y-o-Y (down 2.4 percent Q-o-Q) to Rs 3,073.1 crore, according to Prabhudas Lilladher.

  • Accumulate Glenmark Pharmaceuticals target of Rs 575: Geojit Nov 18, 2021 03:02 PM IST

    Accumulate Glenmark Pharmaceuticals target of Rs 575: Geojit

    Geojit recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 575 in its research report dated November 18, 2021.

  • Accumulate Glenmark Pharmaceuticals; target of Rs 600: Prabhudas Lilladher Nov 16, 2021 02:58 PM IST

    Accumulate Glenmark Pharmaceuticals; target of Rs 600: Prabhudas Lilladher

    Prabhudas Lilladher recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 600 in its research report dated November 16, 2021.

  • Glenmark Pharma share price falls 3%; Morgan Stanley remains 'underweight' Nov 16, 2021 10:46 AM IST

    Glenmark Pharma share price falls 3%; Morgan Stanley remains 'underweight'

    Glenmark Pharmaceuticals has been listed on the Dow Jones Sustainability Index under the category of emerging markets for the fourth consecutive year, the company has said

  • Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher Oct 06, 2021 06:00 PM IST

    Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher

    Net Sales are expected to decrease by 4.2 percent Y-o-Y (down 5.4 percent Q-o-Q) to Rs 2,786.7 crore, according to Prabhudas Lilladher.

  • Buy Glenmark Pharmaceuticals; target of Rs 680: ICICI Direct Aug 19, 2021 01:02 PM IST

    Buy Glenmark Pharmaceuticals; target of Rs 680: ICICI Direct

    ICICI Direct is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 680 in its research report dated August 16, 2021.

  • Glenmark Life Sciences IPO: Traction in complex APIs holds re-rating potential Jul 27, 2021 09:47 AM IST

    Glenmark Life Sciences IPO: Traction in complex APIs holds re-rating potential

    In order to address the opportunities in oncology, peptides and iron compounds, Glenmark Life Science plans to build an R&D pipeline in the coming years

  • Glenmark Life Sciences IPO opens today, should you subscribe? Jul 27, 2021 09:26 AM IST

    Glenmark Life Sciences IPO opens today, should you subscribe?

    Glenmark Life Sciences IPO: The company has debt-to-equity of 1.3x with a debt of Rs 916 crore which includes Rs 800 crore payable to Glenmark Pharmaceuticals, post-IPO debt will be negligible.

  • Glenmark Pharma’s API arm Glenmark Life Sciences to launch IPO on July 27, raise around Rs 1,515 crore; listing likely on August 6 Jul 20, 2021 02:04 PM IST

    Glenmark Pharma’s API arm Glenmark Life Sciences to launch IPO on July 27, raise around Rs 1,515 crore; listing likely on August 6

    The move is being seen as a value-unlocking exercise in a niche segment which is fetching attractive valuations and will provide investors the option of betting on a pure play API business. Glenmark Pharma’s stock has risen by 15 per cent in the last 3 months.

  • Buy Glenmark Pharmaceuticals; target of Rs 717: Geojit Jun 04, 2021 02:28 PM IST

    Buy Glenmark Pharmaceuticals; target of Rs 717: Geojit

    Geojit is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 717 in its research report dated June 03, 2021.

  • Reduce Glenmark Pharmaceuticals target of Rs 509: Prabhudas Lilladher Jun 01, 2021 04:14 PM IST

    Reduce Glenmark Pharmaceuticals target of Rs 509: Prabhudas Lilladher

    Prabhudas Lilladher recommended reduce rating on Glenmark Pharmaceuticals with a target price of Rs 509 in its research report dated Jun 01, 2021.

  • What should investors do with Glenmark Pharma post Q4 earnings: Buy, sell or hold? Jun 01, 2021 09:37 AM IST

    What should investors do with Glenmark Pharma post Q4 earnings: Buy, sell or hold?

    Here is what brokerages have to say about the stock and the company after the March quarter earnings

  • Glenmark Pharma Q4 net profit up 6% at Rs 233.87 crore May 29, 2021 01:46 PM IST

    Glenmark Pharma Q4 net profit up 6% at Rs 233.87 crore

    The company had posted a net profit of Rs 220.30 crore in the corresponding period of the previous fiscal, Glenmark said in a late regulatory filing on Friday.

  • Glenmark Pharma’s API arm files papers with Sebi to unlock value via IPO Apr 17, 2021 12:27 PM IST

    Glenmark Pharma’s API arm files papers with Sebi to unlock value via IPO

    Two years ago, Glenmark Pharmaceuticals had attempted to sell a minority stake in its API business to private equity funds but those plans did not fructify. Post the Q3FY21 results, the management indicated that API growth outlook remained strong for the next two-three years owing to a favourable demand-supply scenario.

  • Glenmark Pharmaceuticals gets USFDA nod for generic antipsychotic drug Mar 24, 2021 01:47 PM IST

    Glenmark Pharmaceuticals gets USFDA nod for generic antipsychotic drug

    "The company has received approval from the United States Food and Drug Administration (USFDA) for Chlorpromazine Hydrochloride tablets USP, in the strengths of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg," Glenmark said in a regulatory filing.

  • Glenmark gets $40 million COVID credit line from International Finance Corporation Mar 23, 2021 02:42 PM IST

    Glenmark gets $40 million COVID credit line from International Finance Corporation

    The loan to Glenmark will help it increase the availability of affordable, quality medicines in the country as well in other countries, including treatment for the pandemic.

  • Glenmark gets USFDA nod for generic high blood pressure drug Mar 23, 2021 02:33 PM IST

    Glenmark gets USFDA nod for generic high blood pressure drug

    The company has received final approval from the United States Food & Drug Administration (USFDA) for Diltiazem Hydrochloride extended-release capsules USP, in the strengths of 60 mg, 90 mg, and 120 mg, Glenmark said in a statement.

Sections
ISO 27001 - BSI Assurance Mark